RecruitingNCT06984250
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hybrid Techniques Combining Hypofractionated Whole Breast Radiotherapy With Concomitant Tumor Bed Boost in Patients With Breast Cancer
Sponsor
National Taiwan University Hospital
Enrollment
315 participants
Start Date
Feb 6, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Eligibility
Sex: FEMALEMin Age: 20 YearsMax Age: 85 Years
Inclusion Criteria6
- Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
- Patients undergoing breast-conserving surgery
- Age ≥ 20 years
- Karnofsky Performance Status (KPS) ≥70%
- Life expectancy ≥ 5 years
- Adequate renal and hepatic function
Exclusion Criteria2
- Pregnant patients
- Patients requiring re-irradiation of the thoracic region
Interventions
RADIATIONHypofractionated Radiation Therapy
Hypofractionated breast radiotherapy (HFRT) with hybrid techniques combining field-in-field intensity-modulated RT (FIF-IMRT) to the whole breast with inverse-IMRT for concomitant boost
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06984250
Related Trials
Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
NCT066504231 location
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081193 locations
Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
NCT072339281 location
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
NCT074059315 locations
Mediterranean Diet and Inequality in Early Breast Cancer
NCT070071692 locations